These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 31200835)

  • 21. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.
    Passaro A; Prelaj A; Bonanno L; Tiseo M; Tuzi A; Proto C; Chiari R; Rocco D; Genova C; Sini C; Cortinovis D; Pilotto S; Landi L; Bennati C; Camerini A; Toschi L; Putzu C; Cerea G; Spitaleri G; Cappuzzo F; de Marinis F
    Clin Lung Cancer; 2019 Mar; 20(2):e186-e194. PubMed ID: 30563752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
    Nosaki K; Yoh K; Toyozawa R; Horinouchi H; Morise M; Ohashi K; Murakami H; Satouchi M; Sakakibara-Konishi J; Yano S; Okumura F; Matsumoto S; Shimokawa M; Seto T; Goto K
    Int J Clin Oncol; 2024 Aug; 29(8):1142-1151. PubMed ID: 38758397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
    Kron A; Scheffler M; Wiesweg M; Hummel HD; Kulhavy J; Gatteloehner S; Kollmeier J; Schubart C; Groß T; Demes MC; Keymel S; Joosten M; Merkelbach-Bruse S; Wölwer CB; Tufman A; Kauffmann-Guerrero D; Oeser K; Zehaczek M; Jeratsch U; Wolf J
    Eur J Cancer; 2024 Aug; 207():114158. PubMed ID: 38941869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
    J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
    Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
    Miao K; Zhang X; Wang H; Si X; Zhang L
    Thorac Cancer; 2023 May; 14(13):1162-1170. PubMed ID: 36944506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tepotinib in Non-Small-Cell Lung Cancer with
    Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
    N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
    Wolf J; Souquet PJ; Goto K; Cortot A; Baik C; Heist R; Kim TM; Han JY; Neal JW; Mansfield AS; Gilloteau I; Nwana N; Waldron-Lynch M; Davis KL; Giovannini M; Awad MM
    Clin Lung Cancer; 2023 Nov; 24(7):641-650.e2. PubMed ID: 37741716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.
    Xu Y; Fan Y
    Cancer Biol Ther; 2019; 20(2):145-149. PubMed ID: 30422759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
    Xia Y; Jin R; Li M; Lan F; Zhu H; Yu Y; Miao D; Wang Q; Zhou Y; Selvaggi G; Ying S; Zhang J; Shen H; Le X; Li W
    Cancer Lett; 2023 May; 561():216140. PubMed ID: 36948240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
    Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
    Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.